#immunomedics

Immunomedics to report Q2 results after the bell

Immunomedics (IMMU) is set to report Q2 2019 earnings results today after the market closes. Street estimates the company to post a loss of $0.34 per share on revenue of $0.20 million. Shares of the biopharmaceutical company are up about 1% during the afternoon session today.

Immunomedics stock had appreciated 6% since the beginning of 2019 and depreciated about 16% in the three months period.

(W…

Earnings preview: Immunomedics might deliver lower revenue for Q2

Immunomedics Inc. (IMMU) is scheduled to report second-quarter 2019 earnings results on Monday, February 25, after market close. The consensus estimates are for a loss of $0.34 per share on revenue of $0.20 million. The revenue number reflects a 66% decline from the year-ago quarter. The company has not yet topped earnings estimates over the past four quarters.

A key point to watch out for are…

Immunomedics, Inc. (Nasdaq:IMMU) Breaks 52 Week High Record

Immunomedics, Inc. (Nasdaq:IMMU)

July 19th, 2018

Immunomedics, Inc. closed Wednesday up 1.14%, a $0.29 increase to close on $25.69. Furthermore it hit a new 52 week high of $27.33. The stock continues to trade well at 258% of its 52 week low of $7.17. Immunomedics, Inc. swung 9.50% between low and high. While it is positive news the stock ended higher, the trading volumes were only 0.00% of…

Immunomedics Inc - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Immunomedics Inc - Product Pipeline Review - 2016', provides an overview of the Immunomedics Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immunomedics Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

To Access Browse Full Research Report @: http://www.radiantinsights.com/research/immunomedics-inc-product-pipeline-review-2016

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Immunomedics Inc

The report provides overview of Immunomedics Inc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Immunomedics Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Immunomedics Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate Immunomedics Inc's strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Immunomedics Inc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Immunomedics Inc's pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To Access Request A Sample Copy Of This Report at: www.radiantinsights.com/research/immunomedics-inc-product-pipeline-review-2016/request-sample

About Radiant Insights: Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

  (RTTNews) – Immunomedics, Inc. (IMMU), a biopharmaceutical company focusing mainly on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, said its antibody-drug conjugate for solid cancer therapy, IMMU-132, has received orphan drug status from the Office of Orphan Products Development of the U.S. Food and Drug…